Literature DB >> 28468893

Continuous renal replacement therapy: a potential source of calories in the critically ill.

Andrea M New1, Erin M Nystrom2, Erin Frazee2, John J Dillon3, Kianoush B Kashani3,4, John M Miles5.   

Abstract

Background: Overfeeding can lead to multiple metabolic and clinical complications and has been associated with increased mortality in the critically ill. Continuous venovenous hemofiltration (CVVH) represents a potential source of calories that is poorly recognized and may contribute to overfeeding complications.Objective: We aimed to quantify the systemic caloric contribution of acid-citrate-dextrose regional anticoagulation and dextrose-containing replacement fluids in the CVVH circuit.Design: This was a prospective study in 10 critically ill adult patients who received CVVH from April 2014 to June 2014. Serial pre- and postfilter blood samples (n = 4 each) were drawn and analyzed for glucose and citrate concentrations on each of 2 consecutive days.
Results: Participants included 5 men and 5 women with a mean ± SEM age of 61 ± 4 y (range: 42-84 y) and body mass index (in kg/m2) of 28 ± 2 (range: 18.3-36.2). There was generally good agreement between data on the 2 study days (CV: 7-11%). Mean ± SEM pre- and postfilter venous plasma glucose concentrations in the aggregate group were 152 ± 10 and 178 ± 9 mg/dL, respectively. Net glucose uptake from the CVVH circuit was 54 ± 5 mg/min and provided 295 ± 28 kcal/d. Prefilter plasma glucose concentrations were higher in patients with diabetes (n = 5) than in those without diabetes (168 ± 12 compared with 140 ± 14 mg/dL; P < 0.05); however, net glucose uptake was similar (46 ± 8 compared with 61 ± 6 mg/min; P = 0.15). Mean ± SEM pre- and postfilter venous plasma citrate concentrations were 1 ± 0.1 and 3.1 ± 0.2 mmol/L, respectively. Net citrate uptake from the CVVH circuit was 60 ± 2 mg/min and provided 218 ± 8 kcal/d.Conclusions: During CVVH there was a substantial net uptake of both glucose and citrate that delivered exogenous energy and provided ∼512 kcal/d. Failure to account for this source of calories in critically ill patients receiving nutrition on CVVH may result in overfeeding.
© 2017 American Society for Nutrition.

Entities:  

Keywords:  CRRT; CVVH; anticoagulation; caloric uptake; citrate; nutrition

Mesh:

Substances:

Year:  2017        PMID: 28468893      PMCID: PMC6546225          DOI: 10.3945/ajcn.116.139014

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  29 in total

Review 1.  Anticoagulation in continuous renal replacement therapy.

Authors:  M Schetz
Journal:  Contrib Nephrol       Date:  2001       Impact factor: 1.580

Review 2.  Energy expenditure in hospitalized patients: implications for nutritional support.

Authors:  John M Miles
Journal:  Mayo Clin Proc       Date:  2006-06       Impact factor: 7.616

3.  Nutritionally associated increased carbon dioxide production. Excess total calories vs high proportion of carbohydrate calories.

Authors:  S S Talpers; D J Romberger; S B Bunce; S K Pingleton
Journal:  Chest       Date:  1992-08       Impact factor: 9.410

4.  No, the glycaemic target in the critically ill should not be < or = 6.1 mmol/l.

Authors:  J M Miles; M M McMahon; W L Isley
Journal:  Diabetologia       Date:  2007-12-20       Impact factor: 10.122

Review 5.  Metabolic aspects of continuous renal replacement therapies.

Authors:  W Druml
Journal:  Kidney Int Suppl       Date:  1999-11       Impact factor: 10.545

Review 6.  Metabolic complications of parenteral nutrition in adults, part 1.

Authors:  Imad F Btaiche; Nabil Khalidi
Journal:  Am J Health Syst Pharm       Date:  2004-09-15       Impact factor: 2.637

7.  Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients.

Authors:  James Stephen Krinsley
Journal:  Mayo Clin Proc       Date:  2003-12       Impact factor: 7.616

8.  Copper, selenium, zinc, and thiamine balances during continuous venovenous hemodiafiltration in critically ill patients.

Authors:  Mette M Berger; Alan Shenkin; Jean-Pierre Revelly; Eddie Roberts; M Christine Cayeux; Malcolm Baines; Rene L Chioléro
Journal:  Am J Clin Nutr       Date:  2004-08       Impact factor: 7.045

9.  Leg and splanchnic arteriovenous differences of plasma citrate in exercising man.

Authors:  T T Nielsen; P E Thomsen
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1979-01

10.  Improving the delivery of continuous renal replacement therapy using regional citrate anticoagulation.

Authors:  R Swartz; D Pasko; J O'Toole; B Starmann
Journal:  Clin Nephrol       Date:  2004-02       Impact factor: 0.975

View more
  5 in total

1.  Calorie provision from citrate anticoagulation in continuous renal replacement therapy in critical care.

Authors:  Alice R Rogers; Bethan Jenkins
Journal:  J Intensive Care Soc       Date:  2020-06-26

2.  Bioenergetic Balance of Continuous Venovenous Hemofiltration, a Retrospective Analysis.

Authors:  Joop Jonckheer; Alex Van Hoorn; Taku Oshima; Elisabeth De Waele
Journal:  Nutrients       Date:  2022-05-18       Impact factor: 6.706

3.  [Metabolic management and nutrition in critically ill patients with renal dysfunction : Recommendations from the renal section of the DGIIN, ÖGIAIN, and DIVI].

Authors:  W Druml; M Joannidis; S John; A Jörres; M Schmitz; J Kielstein; D Kindgen-Milles; M Oppert; V Schwenger; C Willam; A Zarbock
Journal:  Med Klin Intensivmed Notfmed       Date:  2018-05-03       Impact factor: 0.840

4.  Volume based feeding versus rate based feeding in the critically ill: A UK study.

Authors:  Mina Bharal; Sally Morgan; Tariq Husain; Katerina Hilari; Charlie Morawiec; Kirsty Harrison; Paul Bassett; Alison Culkin
Journal:  J Intensive Care Soc       Date:  2019-05-09

5.  The association of intravenous insulin and glucose infusion with intensive care unit and hospital mortality: a retrospective study.

Authors:  Sigrid C van Steen; Saskia Rijkenberg; Peter H J van der Voort; J Hans DeVries
Journal:  Ann Intensive Care       Date:  2019-02-11       Impact factor: 6.925

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.